Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation

S Vannaprasaht, S Reungjui, D Supanya… - Clinical …, 2013 - Elsevier
Abstract Background Cytochrome P450 (CYP) 3A4 and 3A5 are major isoforms involved in
the metabolism of tacrolimus, with the CYP3A5 gene being more polymorphic. It is …

Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean …

JH Cho, YD Yoon, JY Park, EJ Song, JY Choi… - Transplantation …, 2012 - Elsevier
BACKGROUND: Tacrolimus is a substrate of cytochrome P450 3A (CYP3A) and P-
glycoprotein (P-gp), encoded by the CYP3A and ATP-binding cassette subfamily B member …

Metabolic drug interactions with immunosuppressants

K Monostory - Organ donation and transplantation: current status …, 2018 - books.google.com
Organ transplantation has become a routine clinical practice for patients with endstage
disease of liver, kidney, heart, or lung. Although improved immunosuppressant therapy …

ABCB1 haplotype influences the sirolimus dose requirements in Chinese renal transplant recipients

J Lee, H Huang, Y Chen, X Lu - Biopharmaceutics & Drug …, 2014 - Wiley Online Library
Sirolimus, an immunosuppressive drug used to prevent organ rejection after renal
transplantation, has a narrow therapeutic index and a large inter‐individual variability of …

Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients

S Bandur, J Petrasek, P Hribova, E Novotna… - …, 2008 - journals.lww.com
Background. Bioavailability of tacrolimus (Tac) and cyclosporine is determined by
cytochrome P450IIIA and by P-glycoprotein encoded by the CYP3A4/CYP3A5 and ABCB1 …

Pharmacogenetics of calcineurin inhibitors in renal transplantation

E Coto, B Tavira - Transplantation, 2009 - journals.lww.com
Cyclosporine A and tacrolimus (Tac) are inmunosuppresive drugs with a narrow therapeutic
range. Underdosing is associated with organ rejection, whereas overdosing could result in …

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant …

V Haufroid, M Mourad, V Van Kerckhove… - Pharmacogenetics …, 2004 - journals.lww.com
Cyclosporine and tacrolimus are immunosuppressive drugs largely used in renal
transplantation. They are characterized by a wide inter-individual variability in their …

Genotype and allele frequencies of drug-metabolizing enzymes and drug transporter genes affecting immunosuppressants in the Spanish white population

V Bosó, MJ Herrero, E Buso, J Galán… - Therapeutic drug …, 2014 - journals.lww.com
Interpatient variability in drug response can be widely explained by genetically determined
differences in metabolizing enzymes, drug transporters, and drug targets, leading to different …

[HTML][HTML] Influence of absorption, distribution, metabolism, and excretion genomic variants on tacrolimus/sirolimus blood levels and graft-versus-host disease after …

SK Khaled, JM Palmer, J Herzog, T Stiller… - Biology of Blood and …, 2016 - Elsevier
Allelic variants of genes implicated in drug absorption, distribution, metabolism, and
excretion (ADME) determine the pharmacokinetic variability of many medications and are …

Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients

EY Tamashiro, CR Felipe, FDV Genvigir… - Drug metabolism and …, 2017 - degruyter.com
Background: Polymorphisms in genes encoding for drug-metabolizing enzymes and drug
transporters are among multiple factors that modulate the pharmacokinetic variability of …